Measures kinase inhibitor levels in blood of kidney cancer patients with kidney disease
Measures pazopanib and cabozantinib blood levels in adults with kidney cancer and kidney failure.
Plain-language title generated from the registry record
Registry title: Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
Key facts
- Where
- Marseille, Montpellier, Nîmes, and Toulouse, FranceSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic clear cell kidney cancer who take pazopanib or cabozantinib. It compares people with normal kidney function and with kidney failure.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Metastatic clear cell renal cell carcinoma, with good enough daily function (ECOG 0, 1 or 2). Three groups: no renal failure; moderate chronic renal failure (Clr <60 ml / min, stage 3); severe or terminal chronic renal failure (Clr <30 ml / min, stage 4 and 5), with or without dialysis.
- Earlier treatment
- Must be treated with pazopanib or cabozantinib for metastatic kidney cancer. Must not have joined another study with a research product in the last 30 days.
Main reasons for not taking part
- Taking these drugs for a cancer other than clear cell renal cell carcinoma
- Pregnant or breast-feeding
- Regular follow-up impossible for psychological, family, social or geographic reasons
- Under guardianship, curatorship or safeguard of justice
- Took part in another study with a research product in the last 30 days
Read by machine on 9 November 2026.
Where in France
- Aphm - Hopital La TimoneMarseille, FranceTaking people
- CHU Montpellier - Hôpital St EloiMontpellier, FranceTaking people
- ICM Val d'AurelleMontpellier, FranceTaking people
- CHU de Nîmes - Institut de Cancérologie du GardNîmes, FranceTaking people
- Institut Universitaire du Cancer de Toulouse (IUCT) OncopoleToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut du Cancer de Montpellier - Val d'Aurelle
- Trial code
- NCT04823923
- Record updated
- 12 February 2025
- Original description
The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.Read full original descriptionShow less
Study of the Impact of the Stage of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors (ITK) in Patients Treated for Metastatic Kidney Cancer
The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.
Inclusion: Patient followed for metastatic clear cell renal cell carcinoma; Age ≥18 years old; Performance Status (PS) according to Eastern Cooperative Oncology Group (ECOG) = 0, 1 or 2; Patient treated with a VEGF-R inhibitor: pazopanib or cabozantinib for metastatic kidney cancer; If patient doesn't have renal failure -> group 1, or if patient has chronic renal failure according to the moderate stage Chronic Kidney Disease - Epidemiology (CKD-EPI) formula (Clr <60 ml / min, stage 3) -> group 2, or if patient have chronic renal failure according to the CKD-EPI formula of severe or terminal stage (Clr <30 ml / min, stage 4 and stage 5), with or without dialysis -> group 3; Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures; Patient having given informed, written and express consent; Affiliation to the French Social Security System.
Exclusion: Participation in another clinical study with a research product during the last 30 days before inclusion; Indication other than clear cell renal cell carcinoma for these same ITKs; Pregnant or breast-feeding subjects; Patient whose regular follow-up is impossible for psychological, family, social or geographic reasons,; Patient under guardianship, curatorship or safeguard of justice.